Synthetic Myoglobin-Assisted Oxygenation System
Synthetic Myoglobin-Assisted Oxygenation System (SMAOS)
BUREAU OF COLONIES — BIOMEDICAL SYSTEMS DIVISION (BSD)
NEUROPHYSIOLOGICAL AUGMENTATION DOSSIER — FORMAT 15-G (RESTRICTED)
File Code: BUCOL/BIO-CHEN/AUG-ADI-OXY-MGB-01
Subject: Synthetic Myoglobin-Assisted Oxygenation System (SMAOS)
Owner: Aditi "Adi" Nizhóní Peshlakai
Issued By: Markus Kane
Clearance: Level 5 — Biochemical Interface Systems
Status: Operational — Stable Integration, 2829.06.22 CE
1. GENERAL OVERVIEW
The Synthetic Myoglobin-Assisted Oxygenation System (SMAOS) is a precision biochemical enhancement designed to increase intramuscular oxygen retention and sustain aerobic output under hypoxic or extreme exertion conditions.
The system integrates seamlessly with Adi’s Pharmaceutical Implant and Autonomic Neural Regulators, allowing on-demand secretion of synthetic myoglobin analogs directly into the bloodstream.
This artificial myoglobin, codenamed Hemo-X-7, represents a fourth-generation Martian military biopolymer initially developed for long-range vacuum operations by Lazarus Biogenetics Division. Its presence in Adi’s system is strictly illegal under current Martian Federation biowarfare treaties.
2. COMPOSITION AND MECHANISM
Hemo-X-7 Artificial Myoglobin
- Molecular Formula: C₈₀₀H₁₂₇₀N₂₂₀O₂₄₀Fe₂₀ (approx.)
- Structure: Triply folded protein chain incorporating synthetic porphyrin rings with dual iron-magnesium cores, allowing a 62 % higher oxygen binding affinity than natural human myoglobin.
- Half-Life in Circulation: ~6.5 hours under baseline metabolism; up to 12 hours with neural dampening.
- Color: Deep iridescent crimson (visible under dermal light reflection).
When released, Hemo-X-7 molecules electrostatically bond with natural myoglobin within Adi’s skeletal and cardiac muscle cells, creating a hybrid oxygen buffer network.
This bond temporarily increases her muscle tissue oxygen density by ~140 %, effectively eliminating anaerobic fatigue for several minutes and delaying hypoxia onset by 6–10× compared to baseline augmented humans.
3. INTEGRATION WITH EXISTING SYSTEMS
| System | Interface Type | Function |
|---|---|---|
| Pharma Implant | Bio-microfluidic | Stores 15 mL concentrate (equiv. 1,000 mg Hemo-X-7), timed release under AI Asteria control |
| Neural Net (Asteria) | Neuro-autonomic relay | Calculates oxygen debt and triggers release cascade before lactic buildup |
| Nanite and Nucleobot Systems | Quorum-coordinated modulation | Prevents myoglobin polymer over-binding to hemoglobin |
| Haptic Suit Thermal Regulators | Feedback cooling loop | Offsets heat surge during O₂ oversaturation (prevents protein denaturation) |
The injection is controlled through bio-phased release valves along Adi’s spinal pharma interface. Each micro-pulse release equals ~50 mg Hemo-X-7, calibrated for combat bursts or environmental emergencies (vacuum, high-altitude, or anoxic zones).
4. PERFORMANCE CHARACTERISTICS
| Condition | Duration | Observed Effect |
|---|---|---|
| Combat Burst (Full Release) | 4–7 minutes | Near-total suppression of muscular fatigue; heart rate 120–160 bpm sustained under heavy exertion |
| Sustained Endurance Mode | 30–45 minutes | Enhanced stamina, clarity, and oxygen economy; minor neural euphoria noted |
| Low-Oxygen Atmosphere (≤0.6 atm) | Continuous | Maintains motor function without dizziness or hypoxia |
| Underwater / Vacuum Conditions | ~20 minutes | Blood maintains O₂ transport even in total deprivation |
5. SIDE EFFECTS AND METABOLIC CONSEQUENCES
- Iron Demand Spike: Continuous use increases systemic iron consumption by 200–300 %. Without supplementation, risk of acute iron-deficiency collapse within 72 hours.
- Hematologic Overload: Repeated use can cause transient oxy-toxemia (tissue oxidation damage, micro-lesions in liver and kidney).
- Thermal Instability: During prolonged bursts, body temperature may rise above 42 °C; armor and haptic suit sensors engage emergency cooling.
- Visual Artifacts: Users report violet haloing and “glow” around bright light sources during saturation period (likely cortical cross-signal bleed).
- Withdrawal Phase: Fatigue, myalgia, craving for iron-rich food, irritability, and vivid dreams.
6. MAINTENANCE AND REPLENISHMENT
Hemo-X-7 must be recharged through infusion of Fe²⁺-rich chelates and amino-substrates.
Kane supplies Adi with specialized nutrient vials labeled “Fe-S7/Fe-S8: High Density Carnoferrin Mix”.
These injections are required every 10–12 activations.
Failure to replenish leads to nanite auto-shutdown of the myoglobin release system — a failsafe added by Asteria after initial overuse incidents.
7. PSYCHOPHYSIOLOGICAL OBSERVATIONS
Adi experiences a distinct metallic taste and heightened sensory clarity during activation.
Her pupils constrict to pinpoints, heartbeat becomes audibly rhythmic through her own auditory channels, and neural overlays synchronize to “combat clarity” — a euphoric state where instinct overrides hesitation.
Kane's subject logs note:
“When it kicks in, I stop thinking about breathing.
The air just becomes something I own.” — Field Note: Adi, 2829.06.29 CE
8. PROVENANCE
Recovered fragments of the original Lazarus design schematics indicate the SMAOS project was intended for deep-space infiltration units.
Kane’s possession of the intact module suggests high-level black-market acquisition from the Lazarus Consortium Xenobiology Vaults on Deimos, possibly traded through the Order of the Ferric Heart as payment for rare isotopes.
DIRECTORATE COMMENT – Dr. Elin Marochev, BuCol BSD
“The Hemo-X-7 injector is elegant, efficient, and potentially lethal.
It grants a soldier the lungs of a god and the metabolism of a furnace.
In Adi’s case, that balance is the thin red line between humanity and her machine heart.”
SECURITY AND DISTRIBUTION NOTICE
Distribution: BuCol Biomedical Systems Division, Martian Federation Medical Oversight, and Chendiuria Augmentation Registry.
Restriction: Class 5 — Human Bio-Augment Data.
File Status: Active — Continuous Monitoring Recommended.
Filed Under: AuthKey CHEN-ADI-MGB-01 / 2829.06.22
Comments